BioSpace News Archive

The collaboration, which will leverage Enara’s Dark Antigen™ discovery platform, will work toward discovering and validating novel “Dark Antigens” in up to three tumor types in both lung and gastrointestinal cancer.

How do you find success (and not feeling like you’re drowning) when you have to onboard to a new job virtually? We have a few ideas.

Rising prevalence of cardiovascular diseases is the key factor driving global cardiac safety services market growth.

The 21 distinguished award recipients represent achievements across a wide range of light-based sciences as well as key advancements made by these technologies

GT Molecular , a rapidly expanding molecular diagnostics biotech, has launched two highly sensitive tests for the dangerous UK Variant of SARS-CoV-2 (B.1.1.7) . These novel assays build upon GT Molecular’s clinical background and technology for highly accurate and reliable qPCR and digital PCR detection of SARS-CoV-2 vi

TTC Oncology (“TTC” or the “Company”) CEO and CMO Arek Dudek, MD, PhD, will be participating in the Biotech Showcase virtual conference occurring January 11-15, 2021. Dr. Dudek will be providing a Company overview and update on the Company’s financing needs as well as TTC’s lead product candidate, TTC-352. TTC-352 is a novel, first-in-class and best-in-class orally available small molecule being developed as a treatment for

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported preliminary unaudited revenue results for the quarter and full year ended December 31, 2020.

Incyte (NASDAQ: INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody.

REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced underwritten public offering of 4,260,000 shares of its common stock at a price to the public of $47.00 per share, as well as the exercise in full of the underwriters’ option to purchase 639,000 additional shares at the public offering price

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) will provide a preliminary update on its fourth-quarter and full-year 2020 financial results and the continued pace of its business recovery from the COVID-19 pandemic tomorrow, Jan. 13, 2021, during a fireside chat at 10 a.m. ET at the 39th Annual J.P. Morgan Healthcare Conference.